Condition
MIGS
Total Trials
4
Recruiting
0
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Active Not Recruiting2
Enrolling By Invitation1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05062668Completed
Efficacy and Safety of iStent Inject and Inject W in the Management of Primary Open-angle Glaucoma
NCT07073937Enrolling By Invitation
Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty
NCT06909058Not ApplicableActive Not Recruiting
Postoperative Restrictions for Patients Undergoing Minimally Invasive Gynecologic Procedures
NCT05035394Not ApplicableActive Not Recruiting
Swedish Microinvasive Glaucoma Surgery Study (SMIGS)
Showing all 4 trials